Literature DB >> 21618576

Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.

Nobuhiko Hiraga1, Hiromi Abe, Michio Imamura, Masataka Tsuge, Shoichi Takahashi, C Nelson Hayes, Hidenori Ochi, Chise Tateno, Katsutoshi Yoshizato, Yusuke Nakamura, Naoyuki Kamatani, Kazuaki Chayama.   

Abstract

UNLABELLED: Amino acid (aa) substitutions of core 70 and 91 and in the NS5A (nonstructural protein 5A) interferon sensitivity determining region (ISDR) as well as genetic polymorphisms in the host interleukin-28B (IL28B) locus affect the outcome of interferon (IFN)-based therapies for patients with chronic hepatitis C. The combination of these factors and the quasispecies nature of the virus complicate understanding of the underlying mechanism. Using infectious hepatitis C virus (HCV) genotype 1b clone HCV-KT9, we introduced substitutions at both core aa70 (Arg to Gln) and aa91 (Leu to Met). We also introduced four and nine ISDR aa substitutions into core mutant HCV-KT9. Using human hepatocyte chimeric mice with different IL28B genotypes, we examined the infectivity, replication ability, and susceptibility to IFN of these clones. Although aa substitutions in the ISDR significantly impaired infectivity and replication ability of the virus, core aa70 and 91 substitutions did not. The effect of IFN treatment was similar in core wild-type and mutant viruses. Interestingly, virus titer was significantly higher in mice with the favorable IL28B allele (rs8099917 TT and rs12979860 CC) in the transplanted hepatocytes than in mice with hepatocytes from rs8099917 TG and rs12979860 TT donors (P < 0.001). However, the effect of IFN was significantly greater, and intrahepatic expression levels of IFN-stimulated genes were significantly higher in mice with the favorable IL28B allele.
CONCLUSION: Our data suggest that HCV replication levels and response to IFN are affected by human hepatocyte IL28B single-nucleotide polymorphism genotype and mutations in the ISDR. The mechanism underlying the clinically observed association of wild-type core protein in eradication-favorable host cells should be investigated further.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21618576     DOI: 10.1002/hep.24453

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

1.  Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.

Authors:  Tomoko Date; Takanobu Kato; Junko Kato; Hitoshi Takahashi; Kenichi Morikawa; Daisuke Akazawa; Asako Murayama; Keiko Tanaka-Kaneko; Tetsutaro Sata; Yasuhito Tanaka; Masashi Mizokami; Takaji Wakita
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

Review 2.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

Review 3.  Hepatitis C virus genetic variability and evolution.

Authors:  Natalia Echeverría; Gonzalo Moratorio; Juan Cristina; Pilar Moreno
Journal:  World J Hepatol       Date:  2015-04-28

4.  Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection.

Authors:  Yuji Ishida; Masakazu Kakuni; Bo-Ram Bang; Go Sugahara; Daryl T-Y Lau; Chise Tateno-Mukaidani; Meng Li; Michael Gale; Takeshi Saito
Journal:  J Interferon Cytokine Res       Date:  2019-03       Impact factor: 2.607

5.  Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.

Authors:  Evguenia S Svarovskaia; Ross Martin; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  J Clin Microbiol       Date:  2012-07-25       Impact factor: 5.948

6.  Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy.

Authors:  Zhongjie Hu; Ying Liu; Lixia Qiu; Zuopeng Fan; Wei Nie; Shan Liang; Ronghua Jin
Journal:  Virol J       Date:  2015-12-18       Impact factor: 4.099

Review 7.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

8.  Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.

Authors:  Tsunamasa Watanabe; Fuminaka Sugauchi; Yasuhito Tanaka; Kentaro Matsuura; Hiroshi Yatsuhashi; Shuko Murakami; Sayuki Iijima; Etsuko Iio; Masaya Sugiyama; Takashi Shimada; Masakazu Kakuni; Michinori Kohara; Masashi Mizokami
Journal:  Gut       Date:  2012-11-07       Impact factor: 23.059

9.  Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression.

Authors:  Megumi Tasaka-Fujita; Nao Sugiyama; Wonseok Kang; Takahiro Masaki; Takahiro Masaski; Asako Murayama; Norie Yamada; Ryuichi Sugiyama; Senko Tsukuda; Koichi Watashi; Yasuhiro Asahina; Naoya Sakamoto; Takaji Wakita; Eui-Cheol Shin; Takanobu Kato
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

10.  Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.

Authors:  Ran Chen; Michelle Kobewka; William Addison; Gerald Lachance; D Lorne Tyrrell
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.